Mesothelioma gemcitabine is a chemical drug, a chemotherapy drug, which has proved to be active against mesothelioma cancer cells, along with other similar agents, such as ONCONASE and doxorubicin. It has only been tested “in vitro”, but results are promising and doctors are directing their whole attention towards thoroughly examining gemcitabines' full potential.
ONCONASE and gemcitabine are also tested against malignant mesothelioma, and it is known that onconase has reached phase 3b of clinical trials. Gemcitabine is only effective if received in a certain dose, over a specific period of time, depending on the mesothelioma cancer stage of the disease.
Gemcitabine chemotherapy will most probably be administered together with onconase and\or doxorubicin, because studies haves shown that effective grows. Each of the drugs has a different effect and if combined, the cancer will be easier to deal with. Doxorubicin is known to be able to shrink tumors, ONCONASE stops cancer cells from developing further and gemcitabine acts as a break down agent, it helps destroy mesothelioma cancer cells before they become malignant.
Clinical trials of Gemcitabine with Mesothelioma
Clinical trials of gemcitabine and testing on mesothelioma patients together with other drugs showed the following results:
- positive treatment response to a group of 20 patients was 0%
- to another group of 20 patients, positive treatment response was 7%
- a final group of 20 patients showed an improved positive treatment response percentage of 31%
These results are getting better and better with each future patient group, but gemcitabine needs to be delivered in combination with at least one other chemotherapy drug to be effective. Scientists say that mesothelioma will only respond well at a combination of several agents and chemotherapy drugs.
Further testing of gemcitabine will involve the combination with other drugs, such as ALIMTA (pemetrexed) and novelbine, mesothelioma drugs that have already proved their effectiveness. Side effects of gemcitabine have not yet been studied, but apparently they are similar to other mesothelioma chemotherapy drugs. Doctors await further test groups to be able to state a clear conclusion about this.
Get gemcitabine treatment against mesothelioma
Gemcitabine has not yet been approved by the FDA (Food and Drug Administration), so it is not covered by insurance, but if a patient shows its' interest for the testing conducted, he or she has a chance of being some of the lucky ones that may receive gemcitabine mesothelioma treatment for free.
Need further information about gemcitabine? Contact asbestosis and mesothelioma centers and we will gladly answer any questions you might have, free of cost.